Printer Friendly

Research and Markets: Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018.

DUBLIN -- Research and Markets ( has announced the addition of GlobalData 's new report "Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering.

The Osteoporosis Therapeutics Market is Forecast to Show Moderate Growth Throughout 2018

GlobalData, the industry analysis specialist, has released its new report, Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global osteoporosis therapeutics market.

GlobalData analysis shows that the global osteoporosis therapeutics market stood at $6.9 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 4.5% to reach $8.5 billion in 2010. GlobalData forecasts that the global osteoporosis therapeutics market will grow moderately at a CAGR of 3.3% over the next eight years to reach $11.1 billion by 2018. The current competitive landscape consists mainly of bisphosphonates, selective estrogen receptor modulators (SERM), receptor activator of nuclear factor kappa-B (RANK) ligand (RANKL) inhibitor drugs and hormone therapy, which includes parathyroid hormone apart from estrogen and progesterone.

The expected moderate growth can be attributed to the increase in awareness, an ageing population and the launch of prominent pipeline molecules such as Odanacatib (MK-0822) and NB S101.


* Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) osteoporosis therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.

* Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as osteoclast activity inhibitors, osteoclast activity promoters, bone anabolic agents, SERMs, SARMs, RANKL inhibitors, dual acting bone agents, PTH release stimulator, cathepsin K inhibitor, bone morphogenetic protein signaler, aminobisphosphonate, DKK1 Protein inhibitor and osteoblast level promotor

* Analysis of the current and future competition in the seven key countries.

* Insightful review of the key industry drivers, restraints and challenges.

* Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the osteoporosis therapeutics therapeutics market.

* Analysis of key recent licensing and partnership agreements.

Companies Mentioned:

* Amgen Inc.

* Astellas Pharma, Inc.

* EffRx, Inc.

* Merck & Co. Inc.

* Novartis AG

* Osteologix, Inc.

* Pfizer Inc.

* Radius Health, Inc

* Tarsa Inc.

* Zydus Cadila Healthcare Limited

Reasons to buy:

* Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

* Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global osteoporosis therapeutics market in future.

* Identify emerging players with potentially strong product portfolios and create effective counter-strategies.

* Organize your sales and marketing efforts.

For more information visit
COPYRIGHT 2012 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 18, 2012
Previous Article:Research and Markets: World Emerging Sensors Markets.
Next Article:Research and Markets: Nanostructured Materials and Nanotechnology V: Ceramic Engineering and Science Proceedings (Volume 32, Issue 7).

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters